Pelthos Therapeutics Inc. (PTHS) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$17.32M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$13.09M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$15.36M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$3.23M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$17.32M | (m) | $15.60M | (m) | $2.00K* | -$7.66M* | $3.61M | $600.00K | $27.67M | $0.00 |
| 2026-03-31 | Reported | (m) | -$13.09M | (m) | $10.91M | (m) | $194.00K | -$13.13M | $1.67M | $186.00K | $21.10M | $0.00 |
| 2025-09-30 | Reported | (m) | -$15.36M | (m) | $294.00K | (m) | (m) | -$15.26M* | $2.32M | $145.00K | $19.63M | -$465.00K |
| 2025-06-30 | Reported | (m) | -$3.23M | (m) | $0.00 | (m) | $0.00* | -$447.00K* | $0.00 | $515.00K | $2.72M | $0.00 |
| 2025-03-31 | Reported | (m) | -$1.83M | (m) | $0.00 | (m) | $0.00 | -$632.00K | $0.00 | $194.00K | $1.64M | $0.00 |
| 2024-09-30 | Reported | (m) | -$2.05M | (m) | (m) | (m) | (m) | -$177.69K* | (m) | $415.00K | $1.63M | (m) |
| 2024-06-30 | Reported | (m) | -$1.76M | (m) | (m) | (m) | (m) | -$2.95M* | (m) | $12.96K | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$1.93M | (m) | (m) | (m) | (m) | -$1.99M | (m) | $466.61K | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$1.29M | (m) | (m) | (m) | (m) | -$257.24K* | (m) | $49.13K | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$777.16K | (m) | (m) | (m) | (m) | -$193.62K* | (m) | $49.95K | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$914.58K | (m) | (m) | (m) | (m) | -$173.37K | (m) | $186.12K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$32.43M | (m) | $16.80M | (m) | $99.00K | -$22.59M | $3.99M | $1.23M | $42.45M | -$7.39M |
| 2024-12-31 | Reported | (m) | -$7.57M | (m) | $0.00 | (m) | $0.00 | -$5.79M | $0.00 | $1.18M | $6.39M | $0.00 |
| 2023-12-31 | Reported | (m) | -$6.86M | (m) | (m) | (m) | (m) | -$981.03K | (m) | $2.58M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$2.32M | (m) | (m) | (m) | (m) | -$1.57M | (m) | $391.73K | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |